HSHironori Shimizu

Hironori Shimizu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hironori Shimizu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transcatheter arterial embolization of the subclavian and axillary artery branches for hemorrhage control

    by Yasuyuki Onishi, Hironori Shimizu, Saya Ando, Hitomi Kawamura, Motofumi Onishi, Takanori Taniguchi, Hiroyoshi Isoda, Yuji Nakamoto

    Objective: To evaluate the effectiveness and safety of transcatheter arterial embolization (TAE) of the branches of the subclavian and axillary arteries for hemorrhage control. Methods: Between January 2015 and June 2022, 35 TAE procedures were performed for hemorrhage from the branches of the subclavian and axillary arteries in 34 patients (22 men, 12 women; 1 male underwent TAE twice; mean age = 76 years). Pre-TAE CT showed hematomas in the chest (n = 25) and abdominal walls (n = 3), shoulder (n = 2), and lower neck (n = 2). CT showed hemothorax in eight cases. Angiographic findings, embolization technique, and technical and clinical success of TAE were retrospectively assessed in all cases. Results: TAE was performed by transfemoral (n = 16), transradial (n = 12), and transbrachial (n = 7) approaches. Angiography revealed contrast media extravasation or pseudoaneurysms in 32 cases (91.4%). The most commonly embolized arteries were the internal thoracic (n = 12), lateral thoracic (n = 6), and thoracoacromial (n = 6) arteries. Technical and clinical success rates were 100 and 85.7%, respectively. A complication (skin necrosis after injection of the liquid embolic agent) developed in only one patient (2.9%) and was conservatively managed. Conclusion: TAE is an effective and safe treatment for hemorrhage from the branches of the subclavian and axillary arteries. Advances in knowledge: Transfemoral approach has been used for TAE of the branches of the subclavian and axillary artery. Transradial and transbrachial approaches can also be considered.


  • Open Access

    Long-term efficacy and risk factors for stent occlusion in portal vein stent placement: a multi-institutional retrospective study

    by Hirotsugu Nakai, Hironori Shimizu, Takanori Taniguchi, Seiya Kawahara, Toshihide Yamaoka, Naoya Sasaki, Hiroyoshi Isoda, Yuji Nakamoto

    Background: Surgical treatment for PV (portal vein) stenosis/occlusion can pose a fatal risk of massive bleeding from severe adhesions and collateral vessel formation. PV stents placement is a minimally invasive and effective procedure for PV stenosis/occlusion, but PV stents sometimes occlude. The relationship between post-stent PV hemodynamics and stent occlusion has not been thoroughly investigated. Certain precautions during PV stent placement may reduce the risk of stent occlusion. This study aimed to evaluate long-term outcomes of PV stent patency and investigate factors including PV hemodynamics associated with stent occlusion. Materials and methods: Thirty-four consecutive patients with PV stenosis/occlusion who underwent PV stent placement in four institutions between December 2006 and February 2021 were retrospectively examined. The primary study endpoints were technical success, clinical success, and cumulative stent patency rate. The secondary endpoints were risk factors of stent occlusion. A univariable Cox proportional hazards model with sixteen variables was used to determine predictors of stent occlusion. Factors with p-value ≤ 0.1 in univariable analysis were included in the multivariable analysis. Alpha was set at 0.05. Results: Technical and clinical success rates were 88.2% and 79.4%, respectively. Six patients (17.7%) experienced stent occlusion. The cumulative stent patency rate at six months, one year, and three years was 79.1%, 79.1%, and 65.9%, respectively. In the univariate analysis, the variables with p-value ≤ 0.1 were lesion length > 4 cm, hepatofugal collateral vein visualization after stent placement, and residual stenosis > 30% after stent placement. In the multivariate analysis, residual stenosis > 30% after stent placement was significantly associated with stent occlusion (hazard ratio, 10.80; 95% confidence interval, 1.08–108.44; p = 0.04). Conclusion: PV stent placement was technically feasible and effective in improving portal hypertension. However, stent occlusion was not uncommon. Residual stenosis > 30% after stent placement was significantly associated with stent occlusion. We should pay attention to correctly assess the range of stenosis and release the stenosis as much as possible.


  • Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report

    by Yuko Someya, Sho Koyasu, Yasuyuki Ohnishi, Tsuyoshi Ohno, Hironori Shimizu, Hiroyoshi Isoda, Yuji Nakamoto

    Epoprostenol is a prostacyclin (prostaglandin I2) analog that causes vasodilation and inhibits platelet aggregation and is used in the management of severe pulmonary arterial hypertension (PAH). We herein report a patient with PAH who developed pancreatic enlargement after the initiation of therapy including epoprostenol. Although it is well known that thyroid enlargement occurs in patients with PAH receiving epoprostenol therapy, the pancreatic findings associated with epoprostenol therapy have not been well described. Although the size of the pancreas was clearly increased, there was no blood data or symptoms suggestive of abnormal pancreatic function and pancreatitis, and the patient’s abdominal complaints improved quickly, despite the continuation of epoprostenol therapy. Eleven months after the start of continuous intravenous epoprostenol infusion therapy, the pancreatic enlargement was still evident on imaging, but there were no abdominal symptoms or elevated pancreatic enzymes. This case highlights the fact that epoprostenol therapy may cause pancreatic changes that mimic acute or autoimmune pancreatitis.


  • Optimizing b-values for accurate depiction of pancreatic cancer with tumor-associated pancreatitis on computed diffusion-weighted imaging

    by Koji Tokunaga, Shigeki Arizono, Hironori Shimizu, Koji Fujimoto, Mariyo Kurata, Sachiko Minamiguchi, Hiroyoshi Isoda, Kaori Togashi


  • Additional benefit of computed diffusion-weighted imaging for detection of hepatic metastases at 1.5T

    by Seiya Kawahara, Hiroyoshi Isoda, Koji Fujimoto, Hironori Shimizu, Akihiro Furuta, Shigeki Arizono, Tsuyoshi Ohno, Rikiya Yamashita, Ayako Ono, Kaori Togashi


  • Non-contrast-enhanced MR portography and hepatic venography with time-spatial labeling inversion pulses: Comparison of imaging with the short tau inversion recovery method and the chemical shift selective method

    by Hironori Shimizu, Hiroyoshi Isoda, Tsuyoshi Ohno, Rikiya Yamashita, Seiya Kawahara, Akihiro Furuta, Koji Fujimoto, Aki Kido, Hiroshi Kusahara, Kaori Togashi


  • Non-contrast-enhanced MR portography with balanced steady-state free-precession sequence and time-spatial labeling inversion pulses: Comparison of imaging with flow-in and flow-out methods

    by Akihiro Furuta, Hiroyoshi Isoda, Rikiya Yamashita, Tsuyoshi Ohno, Seiya Kawahara, Hironori Shimizu, Koji Fujimoto, Aki Kido, Hiroshi Kusahara, Kaori Togashi

    Purpose To compare and evaluate images of non–contrast‐enhanced MR portography acquired with two different methods, the flow‐in and flow‐out methods. Materials and Methods Twenty‐five healthy volunteers were examined using respiratory‐triggered three‐dimensional balanced steady‐state free‐precession (SSFP) with two selective inversion recovery pulses (flow‐in method) and one tagging pulse and one nonselective inversion recovery pulse (flow‐out method). For quantitative analysis, vessel‐to‐liver contrast (Cv‐l) ratios of the main portal vein (MPV), right portal vein (RPV), and left portal vein (LPV) were measured. The quality of portal vein visualization was scored using a four‐point scale. Results The Cv‐ls of the MPV, RPV, and LPV were all significantly higher with the flow‐out than flow‐in method (MPV = 0.834 ± 0.06 versus 0.711 ± 0.10; RPV = 0.861 ± 0.04 versus 0.729 ± 0.11; LPV = 0.786 ± 0.08 versus 0.545 ± 0.22; P < 0.0001). In all analyses of vessel visibility, non–contrast‐enhanced MR portography with the flow‐out method showed higher scores than with the flow‐in method. With the flow‐out method, visual scores of the MPV, RPV, portal vein branches of segments 4 (P4), and 8 (P8) were significantly better than with the flow‐in method (MPV = 3.4 ± 0.7 versus 2.6 ± 0.9; RPV = 4.0 ± 0.0 versus 3.5 ± 0.9; P4 = 2.8 ± 1.3 versus 1.6 ± 1.0; P8 = 4.0 ± 0.0 versus 2.9 ± 1.1; P < 0.05). Conclusion Non–contrast‐enhanced MR portography with the flow‐out method improves the visualization of the intrahepatic portal vein in comparison with the flow‐in method. J. Magn. Reson. Imaging 2014;40:583–587.


  • Comparison of acquired diffusion weighted imaging and computed diffusion weighted imaging for detection of hepatic metastases

    by Hironori Shimizu, Hiroyoshi Isoda, Koji Fujimoto, Seiya Kawahara, Akihiro Furuta, Toshiya Shibata, Kaori Togashi